FIGURE 2.

Progression-free survival (PFS) and overall survival (OS) outcomes for patients with HRAS-mutant, advanced salivary gland cancer who were treated with tipifarnib. Kaplan-Meier survival curves showing (A) PFS measured in months from the time of the initiation of tipifarnib dosing to first instance of disease progression or death (whichever occurred first) or censored at the time of last known follow-up and (B) OS measured in months from the time of the initiation of tipifarnib therapy to death or else censored at the time of last known follow-up. The number of subjects at risk are shown below each curve.